Common Stock Valuation Ratios (Price Multiples)
Quarterly Data
Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- Analysis of Liquidity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Analysis of Geographic Areas
- Enterprise Value to EBITDA (EV/EBITDA)
- Enterprise Value to FCFF (EV/FCFF)
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Selected Financial Data since 2005
- Return on Assets (ROA) since 2005
- Price to Operating Profit (P/OP) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Historical Valuation Ratios (Summary)
Regeneron Pharmaceuticals Inc., historical price multiples (quarterly data)
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
- Price to Earnings (P/E) Ratio
- The P/E ratio shows an initial absence of data for early 2020, with values starting to be reported from the first quarter of 2021. From March 2021 onwards, the ratio gradually declines from 15.09 to a low of 8.37 by March 2022, indicating improved earnings relative to price during that period. Subsequently, the ratio reverses trend and increases steadily through 2023, peaking at 27.88 in September 2024. After this peak, a notable decline follows, reaching 13.65 by March 2025. This pattern suggests a phase of growing investor optimism or reduced earnings around 2023-2024, followed by a correction or improving earnings outlook by early 2025.
- Price to Operating Profit (P/OP) Ratio
- Similar to the P/E ratio, data begins from early 2021 and initially shows a downward trend from 14.82 to 7.55 between March 2021 and March 2022. This indicates increasing operating profitability relative to price. Thereafter, a significant rise occurs throughout 2023, culminating at 30.86 in September 2024, suggesting a period where operating profits may not have kept pace with price increases or market valuation expansion. Post-peak, a decline takes place, with the ratio moving down to 16.03 by March 2025, signaling some rebound in operating profit relative to price or valuation adjustment.
- Price to Sales (P/S) Ratio
- The P/S ratio follows a pattern consistent with the earnings and operating profit ratios, beginning at 6.24 in early 2021 and declining steadily to 4.2 by March 2022, indicating price adjustments or increasing sales. In 2023, the metric trends upwards, reaching a high of 8.93 in September 2024, which could reflect stronger market valuations relative to sales. After this peak, it decreases to 4.36 by March 2025, pointing to either increased sales, decreased prices, or a combination thereof. Overall, the fluctuations suggest periods of varying market confidence and operational performance.
- Price to Book Value (P/BV) Ratio
- The P/BV ratio is available starting from March 2020 and generally shows a downward trend throughout the observed periods. The ratio decreases from 5.33 in March 2020 to 2.09 by March 2025, with minor fluctuations around 3 to 4 values in between. This consistent reduction suggests a declining market valuation relative to book value, possibly due to increased book value accumulation, declining investor optimism, or market re-pricing of underlying assets. The relative steadiness and gradual decline contrast with the more volatile earnings and sales multiples.
Price to Earnings (P/E)
Regeneron Pharmaceuticals Inc., historical P/E calculation (quarterly data)
| Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | ||||||||||||||||||||||||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||||
| Net income (in thousands) | ||||||||||||||||||||||||||||
| Earnings per share (EPS)2 | ||||||||||||||||||||||||||||
| Share price1, 3 | ||||||||||||||||||||||||||||
| Valuation Ratio | ||||||||||||||||||||||||||||
| P/E ratio4 | ||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||
| P/E Ratio, Competitors5 | ||||||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Data adjusted for splits and stock dividends.
2 Q1 2025 Calculation
EPS
= (Net incomeQ1 2025
+ Net incomeQ4 2024
+ Net incomeQ3 2024
+ Net incomeQ2 2024)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Regeneron Pharmaceuticals Inc. Quarterly or Annual Report.
4 Q1 2025 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =
5 Click competitor name to see calculations.
The share price experienced notable fluctuations over the observed periods. Initially, from the first quarter of 2020 through mid-2021, the price exhibited a general upward trend, moving from $574.37 to $647.63, with a brief decline around the end of 2020. This was followed by a phase of increased volatility, where the share price reached a peak of $936.33 by the end of 2023 and continued to rise to $1,093.14 by the second quarter of 2024. However, after this high point, the price entered a downward trajectory, declining sharply to $568.91 by the first quarter of 2025.
Earnings per share (EPS) data, although missing for several early quarters, starts from the first quarter of 2021 and shows an initial increase from $32.79 to a peak of $74.40 by the first quarter of 2022. After this peak, there is a noticeable decline and subsequent stabilization in EPS figures, fluctuating between approximately $36 and $42 from late 2022 through to early 2025. This moderate fluctuation suggests some variability in profitability but no consistent growth trend in the later periods.
The price-to-earnings (P/E) ratio shows a declining trend from 15.09 in early 2021 to a low of 8.37 by the end of 2021, indicating that the share price was valuing earnings more conservatively during this period. Subsequently, the P/E ratio rose again substantially, peaking at 27.88 in the third quarter of 2024. This increase in the P/E ratio occurred despite the relatively stable EPS levels, implying that the share price growth was outpacing earnings increases. Toward the end of the dataset, the P/E ratio decreased to 13.65 in the first quarter of 2025, consistent with the sharp decline in the share price during the same timeframe.
In summary, the company exhibited a share price pattern of growth followed by volatility and then a significant decline. EPS peaked early and then stabilized without sustained growth, while the P/E ratio's movements suggest changing market sentiment and valuation dynamics independent of earnings performance. The decoupling between share price and EPS in certain periods highlights fluctuations in market expectations or investor confidence.
- Share Price
- Overall upward trend initially, peaking in mid-2024, followed by a notable decrease by early 2025.
- Earnings per Share (EPS)
- Increased sharply through early 2022, then stabilized with moderate fluctuations through early 2025.
- Price-to-Earnings (P/E) Ratio
- Downward trend in early periods, followed by a significant increase peaking in late 2024, before declining again with share price drops.
Price to Operating Profit (P/OP)
Regeneron Pharmaceuticals Inc., historical P/OP calculation (quarterly data)
| Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | ||||||||||||||||||||||||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||||
| Income from operations (in thousands) | ||||||||||||||||||||||||||||
| Operating profit per share2 | ||||||||||||||||||||||||||||
| Share price1, 3 | ||||||||||||||||||||||||||||
| Valuation Ratio | ||||||||||||||||||||||||||||
| P/OP ratio4 | ||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||
| P/OP Ratio, Competitors5 | ||||||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Data adjusted for splits and stock dividends.
2 Q1 2025 Calculation
Operating profit per share
= (Income from operationsQ1 2025
+ Income from operationsQ4 2024
+ Income from operationsQ3 2024
+ Income from operationsQ2 2024)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Regeneron Pharmaceuticals Inc. Quarterly or Annual Report.
4 Q1 2025 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =
5 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several notable trends in the share price, operating profit per share, and the corresponding price-to-operating-profit (P/OP) ratio over the observed periods.
- Share Price Trend
- The share price exhibited a fluctuating pattern with an initial increase from $574.37 in March 2020 to a peak of $647.63 in September 2021. Following this peak, there was a period of relative stability around the $620-$780 range through 2022 and 2023, including a significant high of $936.33 in December 2023 and $1093.14 in June 2024. However, beginning in the third quarter of 2024, a notable decline occurred, with the share price decreasing to $568.91 by March 2025. This indicates heightened volatility, particularly in the most recent quarters.
- Operating Profit Per Share
- Operating profit per share first appears in March 2020 and shows a generally upward trend from $33.39 in March 2020 to a peak of $82.78 in June 2022. This peak is followed by a decline from the third quarter of 2022 onwards, gradually dropping to the mid-30s range by March 2025. This suggests that while operational profitability strengthened initially, it faced pressures leading to a reduction over the latter periods.
- Price-to-Operating-Profit (P/OP) Ratio
- The P/OP ratio started from a high 14.82 in March 2020, declining to a trough of 7.55 by March 2022, indicating improved valuation relative to operating earnings during that time. Post-March 2022, the ratio increased significantly, reaching a peak of 30.86 in September 2024, before declining again to 16.03 by March 2025. This fluctuation suggests changing investor sentiment or expectations regarding future profitability, with the market valuing the stock more expensively relative to its earnings in the middle period, then correcting downwards recently.
- Interrelationships and Insights
- The inverse movement between operating profit per share and the P/OP ratio after mid-2022 illustrates a period where the share price may have outpaced earnings growth, possibly driven by market optimism or speculative factors. This is supported by the simultaneous increase in share price up to June 2024, followed by a sharp decline. The subsequent drop in both operating profit per share and share price towards early 2025 points to potential operational challenges or changing market conditions impacting valuation and performance.
Price to Sales (P/S)
Regeneron Pharmaceuticals Inc., historical P/S calculation (quarterly data)
| Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | ||||||||||||||||||||||||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||||
| Revenues (in thousands) | ||||||||||||||||||||||||||||
| Sales per share2 | ||||||||||||||||||||||||||||
| Share price1, 3 | ||||||||||||||||||||||||||||
| Valuation Ratio | ||||||||||||||||||||||||||||
| P/S ratio4 | ||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||
| P/S Ratio, Competitors5 | ||||||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Data adjusted for splits and stock dividends.
2 Q1 2025 Calculation
Sales per share
= (RevenuesQ1 2025
+ RevenuesQ4 2024
+ RevenuesQ3 2024
+ RevenuesQ2 2024)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Regeneron Pharmaceuticals Inc. Quarterly or Annual Report.
4 Q1 2025 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =
5 Click competitor name to see calculations.
The share price exhibited fluctuations over the analyzed periods, with an initial rise from US$574.37 at the end of March 2020 to a peak of US$780.86 in December 2022. Following this peak, the share price showed volatility, reaching a high of US$1,093.14 in June 2024 before declining to US$568.91 by March 2025. This indicates periods of significant growth followed by a notable contraction in the latest quarters.
Sales per share data, available from March 2021 onwards, demonstrated a generally upward trend from US$79.31 to US$130.46 by March 2025. There was a steady increase through the periods, with minor fluctuations around 120 US$ per share in the mid-phase, followed by a more consistent rise towards the end of the timeline. This suggests improving revenue generation relative to the shares outstanding.
The price-to-sales (P/S) ratio showed considerable variability across the periods. Starting at 6.24 in March 2021, it declined steadily to a low of 4.2 by March 2022, suggesting the share price was relatively undervalued in relation to sales at that point. Subsequently, the P/S ratio increased sharply to 8.93 in September 2024, indicating a period where the share price rose faster than sales per share. The ratio then retracted to 4.36 by March 2025, reflecting decreased market valuation relative to sales in the most recent quarter.
In summary, the company experienced growth in sales per share with corresponding fluctuations in share price and valuation multiples. There were phases where the market price outpaced sales growth, as indicated by elevated P/S ratios, followed by corrections where valuation metrics declined. The latest data suggests a decrease in both share price and valuation relative to sales, despite sustained sales per share improvements.
Price to Book Value (P/BV)
Regeneron Pharmaceuticals Inc., historical P/BV calculation (quarterly data)
| Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | ||||||||||||||||||||||||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||||
| Stockholders’ equity (in thousands) | ||||||||||||||||||||||||||||
| Book value per share (BVPS)2 | ||||||||||||||||||||||||||||
| Share price1, 3 | ||||||||||||||||||||||||||||
| Valuation Ratio | ||||||||||||||||||||||||||||
| P/BV ratio4 | ||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||
| P/BV Ratio, Competitors5 | ||||||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Data adjusted for splits and stock dividends.
2 Q1 2025 Calculation
BVPS = Stockholders’ equity ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Regeneron Pharmaceuticals Inc. Quarterly or Annual Report.
4 Q1 2025 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =
5 Click competitor name to see calculations.
- Share Price
- The share price exhibited notable fluctuations across the observed periods. Initially, from March 2020 to December 2020, it declined from 574.37 USD to 494.9 USD, reflecting a downward trend. Following this, from early 2021 through late 2023, the share price generally increased, reaching a peak of 936.33 USD in December 2023. However, subsequent periods showed volatility with a sharp rise to 1093.14 USD in June 2024, followed by a decline, ending at 568.91 USD by March 2025. This indicates considerable market variability and heightened sensitivity to external or internal factors impacting the company's valuation.
- Book Value per Share (BVPS)
- The book value per share demonstrated a consistent and steady upward trajectory over the entire period. Starting at 107.83 USD in March 2020, BVPS increased progressively each quarter, reaching 272.19 USD by March 2025. This steady increase suggests ongoing accumulation of net asset value, reflecting sustained growth in company equity and potentially effective capital management.
- Price-to-Book Value Ratio (P/BV)
- The P/BV ratio showed a general decreasing trend from 5.33 in March 2020 to 2.09 in March 2025. There were periods of fluctuation within this overall downward trend; for instance, it dropped sharply from 7.34 in June 2020 to 3.6 by December 2021, with minor rebounds around mid-2024. The decline in P/BV ratio suggests that the share price increase has not kept pace with the growth in book value, indicating a possible market perception of reduced overvaluation or increased investor caution regarding future growth prospects relative to the company’s book value.
- Summary
- The data reveals an initial decline in share price followed by a strong recovery and subsequent volatility. In contrast, the book value per share consistently increased, highlighting solid equity growth. The price-to-book ratio steadily decreased over time, emphasizing a growing alignment between the company's market price and its underlying book value. Collectively, these trends suggest a maturing valuation profile with potential shifts in investor sentiment and market dynamics impacting the stock price independently of fundamental book value growth.